Form 4: Entero Therapeutics CEO James Sapirstein Sells Shares to Cover Tax Obligations

Entero Therapeutics CEO James Sapirstein sold 1,289 shares of common stock on July 2, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• On July 2, 2024, James Sapirstein, the Chairman and CEO of Entero Therapeutics, Inc., sold 1,289 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $1.07, with individual transactions ranging from $1.05 to $1.16.
• Following the transaction, Sapirstein beneficially owns 35,816 shares, including unvested RSUs.
• The sale was mandated by Entero's policy requiring tax withholding obligations to be funded through a 'sell to cover' transaction, indicating it was not a discretionary sale by Sapirstein.

Sentiment

Score: 6

Explanation: The document reflects a neutral event (covering tax obligations) and doesn't indicate any significant positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors regarding their trading activities. This particular transaction appears to be routine, related to tax obligations on vested equity.

Stakeholder Impact

• The sale of shares by an insider could have a minor negative impact on shareholder sentiment, but the reason for the sale (tax obligations) mitigates this concern.

Key Dates

Keywords

Entero Therapeutics, James Sapirstein, stock sale, Form 4, tax withholding, RSUs, ENTRO